Cancer Conversations™: PARP Inhibitors in Ovarian Cancer

Join us for this online, live talk show–style Webinar as expert faculty discuss the most recent data on PARP Inhibitors for patients with ovarian cancer, including information on the newest approvals and emerging treatment options.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Welcome and Introduction

Genetic Drivers of Ovarian Oncogenesis

New Advances in the Frontline Treatment of Ovarian Cancer

  • New and emerging indications for PARP inhibitors
  • PARP inhibitor monotherapy and in combination

Clinical Application of PARP Inhibitors

  • Sequencing PARP inhibitors
  • Managing PARP inhibitor-related adverse events

Expert Views on The Future of PARP Inhibitors in Ovarian Cancer

  • Combinations of PARP inhibitors with other anticancer therapies in ovarian cancer
  • PARP plus novel Wee1 inhibitors

Final Thoughts and Takeaways


Date / Time
Event Details


Program Director
Ursula Matulonis, MD

Chief, Division of​ Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Robert L. Coleman, MD, FACOG, FACS

Gynecologic Oncologist & Chief Scientific Officer
US Oncology, US Oncology Research
The Woodlands, Texas

Kathleen Moore, MD

Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center
University of Oklahoma
Oklahoma City, Oklahoma

Goal Statement
The goal of this activity is to educate gynecologic oncologists, medical oncologists, and other healthcare professionals about the recent developments in the care of ovarian cancer and incorporating new data and new therapies into their patient treatment plans.

Target Audience
This program is intended for physicians and other healthcare professionals. This educational program is intended for gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss the current PARP inhibitor indications in ovarian cancer and how those indications can shape treatment plans
  • Evaluate current and emerging practice-changing clinical data on PARP inhibition as single-agent or combination therapies in ovarian cancer
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.